Response to crizotinib in a patient with MET-mutant papillary renal cell cancer after progression on tivantinib

Eur Urol. 2015 Feb;67(2):353-4. doi: 10.1016/j.eururo.2014.10.012. Epub 2014 Oct 27.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, N.I.H., Extramural

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Biopsy
  • Carcinoma, Renal Cell / drug therapy*
  • Carcinoma, Renal Cell / enzymology
  • Carcinoma, Renal Cell / genetics
  • Carcinoma, Renal Cell / pathology
  • Crizotinib
  • Disease Progression
  • Drug Substitution*
  • Humans
  • Immunohistochemistry
  • Kidney Neoplasms / drug therapy*
  • Kidney Neoplasms / enzymology
  • Kidney Neoplasms / genetics
  • Kidney Neoplasms / pathology
  • Male
  • Middle Aged
  • Mutation*
  • Protein Kinase Inhibitors / therapeutic use*
  • Proto-Oncogene Proteins c-met / antagonists & inhibitors*
  • Proto-Oncogene Proteins c-met / genetics*
  • Proto-Oncogene Proteins c-met / metabolism
  • Pyrazoles / therapeutic use*
  • Pyridines / therapeutic use*
  • Pyrrolidinones / therapeutic use*
  • Quinolines / therapeutic use*
  • Time Factors
  • Tomography, X-Ray Computed
  • Treatment Outcome

Substances

  • ARQ 197
  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyridines
  • Pyrrolidinones
  • Quinolines
  • Crizotinib
  • MET protein, human
  • Proto-Oncogene Proteins c-met

Supplementary concepts

  • Papillary renal cell carcinoma, sporadic